PGA - New York State Society of Anesthesiologists, Inc.
 NYSSA Home

  PGA Home

  PGA Archives

  Public

  Professionals

  Press

  Members

  Contact Us



If page does not load completely, please press your "Reload" or "Refresh" button.


Saturday, Dec 12, 2009

MEDICATIONS I NEED TO CONSIDER FOR MY PATIENTS
1:00 pm - 3:30 pm, South Ballroom - 6th Floor
Course Code: SP-09
Speaker: STEVEN L. SHAFER, M.D.

Dr. Shafer - Is a Cofounder, shareholder in PharmacoFore.

Objective(s):
Objective(s): 1. List the indications for mu receptor antagonists in the perioperative period; 2. Formulate a treatment plan for PONV involving one or a combination of anti-emetic agents; 3. Describe the clinical applications of Sugammadex; 4. Devise a plan for renal protection during the perioperative period.



1. What’s New: MU Receptor Antagonists, Fospropofol, Benzos and What’s in the Pipeline?

2. Which Antimetic(s) Should I Use?

3. Muscle Relaxants and the Latest in Total Reversal Agents

4. Fenoldopam and Other Medications for Renal Protection

 
Faculty:
1. STEVEN L. SHAFER, M.D.
2. DAVID A. LUBARSKY, M.D., M.B.A.
3. CYNTHIA A. LIEN, M.D.
4. ROBERT N. SLADEN, M.D.

Cost: $0

Disclosures:

Dr. Lubarsky - Receives consultant fees from Abbott Laboratories and is on the speakers bureau for Grant/Downing Education, MGI Pharma and Schering-Plough.
Dr. Lien - Does not have significant financial relationships with any commercial product, manufacturer or provider.
Dr. Sladen - Receives funded research support from Eli Lilly Company and Scios Inc. as well as consultant fees/salary from Hospira, Inc. (Japan) and Orion Pharma.